Outcomes Among Patients in Brazil Receiving Palbociclib Combinations for HR+/HER2- MBC
NCT05505175 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2023-05-25
Summary
The objective of this study is to describe patient demographics, clinical characteristics, treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy, regardless of combination partner and labelled use in real world settings across Brazil.
Conditions
- Breast Cancer
- Breast Carcinoma
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-30
- Primary Completion
- 2023-05-02
- Completion
- 2023-05-02
Countries
- Brazil
Study Locations
More Related Trials
-
Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC
NCT04937660 ·Status: COMPLETED
-
RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.
NCT04460898 ·Status: COMPLETED
-
A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.
NCT04671615 ·Status: COMPLETED
-
A Biomarker Study of Palbociclib + Fulvestrant for Second, and Third Line of Postmenopausal Women With hr+/her2- Advanced Breast Cancer
NCT03560856 ·Status: UNKNOWN ·Phase: PHASE2
-
Treatment After Palbociclib-containing Regimens
NCT04517318 ·Status: COMPLETED
-
Palbociclib in Real World Practice
NCT03280303 ·Status: COMPLETED
-
Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer
NCT04874025 ·Status: COMPLETED
-
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
NCT02600923 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
NCT01740427 ·Status: COMPLETED ·Phase: PHASE3
-
Ribociclib in Combination With Non-steroidal Aromatase Inhibitors in Patients With Advanced Breast Cancer
NCT05569187 ·Status: COMPLETED
-
Palbociclib Combine With Anti-HER2 Therapy in Triple Positive ABC
NCT05969184 ·Status: UNKNOWN ·Phase: PHASE2
-
Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
NCT02142868 ·Status: NO_LONGER_AVAILABLE
-
A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer
NCT06495164 ·Status: ACTIVE_NOT_RECRUITING
-
Patterns of Treatment and Outcome of Palbociclib Plus Endocrine Therapy
NCT04524728 ·Status: COMPLETED
-
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
NCT05584644 ·Status: COMPLETED
-
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
NCT02297438 ·Status: COMPLETED ·Phase: PHASE3
-
Ibrance Real World Insights
NCT03159195 ·Status: COMPLETED
-
A Retrospective Non-interventional Study of Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib in Denmark
NCT05452798 ·Status: COMPLETED
-
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
NCT03756090 ·Status: UNKNOWN ·Phase: NA
-
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period
NCT05135104 ·Status: UNKNOWN
-
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy
NCT04318223 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
NCT05266105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea
NCT05132101 ·Status: COMPLETED
-
Palbociclib in Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer
NCT02536742 ·Status: COMPLETED ·Phase: PHASE2
-
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT05226871 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2